Most of cancer medicine waits until the tumor is already there. GLP-1 drugs are pointing at something earlier, lowering risk across 10 of the 13 obesity-associated cancers and beating insulin doing it. That is prevention backed by data, and we are not waiting on consensus to act.
Tomorrow on The GoodWill Show — Friday, 1 PM PST
@drgoodyear on two big stories:
🔵Daraxonrasib doubled overall survival in pancreatic cancer at ASCO 2026. Published in NEJM on May 31. What does this mean for the future of chemotherapy?
🔵GLP-1s and the anti-cancer correlation. Ozempic-class drugs are now being linked to lower cancer progression. Real effect, or weight loss in disguise?
Real science. Real implications. Live on X.
@MarioNawfal Vitamin D helps to reduce the tumor remodeling that rebuffs the immune system, like through increase in the immunosuppressive signal IL-10. Yet, most doctors are scared to appropriately dose vitamin D, let alone check it.
GLP-1 drugs are doing more to cancer than the weight loss explains.
The immune effects are real, and we are seeing it play out in tumors that resist almost everything else, which tells me metabolism is not the whole story.
What if the tumor itself could help activate the immune system?
In this episode, Dr. Jason Williams and Dr. Nathan Goodyear discuss recent research from Williams Cancer Institute on pulsed electric field ablation and intratumoral immunotherapy — an innovative approach designed to treat the tumor directly while engaging the body’s immune response.
Watch the full episode to learn more.
https://t.co/h3Rj2tHtVK
Engaging the immune system turns a tumor into an in side you vaccination, or in vivo vaccination. Better stated: we use the tumor to take your immune system to school.
A pancreatic cancer tumor can teach the immune system to find the disease everywhere, not just where the needle went. You have to treat it in place to get that. Take it out and you lose the lesson.
That is the part people miss. We are not removing a lump. We are showing the whole body what to look for.
The science is here. What is missing is reach. A few of us doing this cannot move the needle on a disease that kills this many people this fast. The places with the patients and the funding are the ones that could change the outcome overnight, and they are the slowest to pick it up.